A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

Inclusion Criteria: 1. Participant has given written informed consent to participate in the study in accordance with local regulations 2. Adult male and female participants ≥18 years of age at the Screening Visit 3. Body mass index ≥18.0 to ≤40.0 kilogram per meter square (kg/m\^2) at Screening 4. Diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) with chronic DPNP, at Screening 5. Pain from DPNP present for at least 6 months prior to Screening 6. At the Screening Visit, glycosylated hemoglobin (A1C) must be ≤11%. 7. Stable regimen for the treatment of T1DM or T2DM for ≥3 months prior to Screening 8. Willing to adhere to the prohibitions and restrictions specified in the protocol. Exclusion Criteria: 1. Presence of other painful conditions that may confound assessment or self-evaluation of DPNP 2. History of neurolytic or neurosurgical therapy for DPNP 3. Use of opioid medications for management of DPNP within the 2 months prior to the Screening Visit. 4. Use of prescription topical analgesics (eg, capsaicin) indicated for neuropathic pain within 3 months prior to Screening 5. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) less than 2 weeks prior to Screening